Workflow
in vivo gene editing medicines
icon
Search documents
Editas Medicine Announces First Quarter 2025 Results and Business Updates
GlobeNewswire News Room· 2025-05-12 20:30
Company to share in vivo preclinical data demonstrating the successful use of targeted lipid nanoparticles to deliver HBG1/2 promoter editing cargo to hematopoietic stem and progenitor cells (HSPCs) at ASGCT this week Company will also share in vivo preclinical proof of concept to upregulate expression of a target liver protein to meaningfully reduce a common disease-associated biomarker at ASGCT this week and TIDES next week Remains on track to declare two in vivo gene editing development candidates via ge ...
Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
Globenewswire· 2025-04-28 20:31
CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that five abstracts have been accepted for presentation, including one oral presentation, at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) being held May 13 – 17, 2025, in New Orleans, LA, and virtually. The Company is presenting preclinical data to support its development of transformative in vivo gene editing medicines. Editas Medi ...
Editas Medicine Announces Chief Financial Officer Transition
Globenewswire· 2025-03-20 20:01
Core Points - Editas Medicine announced that CFO Erick J. Lucera will step down effective March 28, 2025, to pursue another opportunity, with Amy Parison appointed as the new CFO [1][2][3] Company Leadership Transition - Amy Parison has been promoted to CFO after serving as Senior Vice President of Finance for two and a half years, demonstrating strong financial decision-making and leadership skills [2][4] - Dr. Gilmore O'Neill, President and CEO, expressed confidence in Parison's ability to lead the company financially and continue its mission of developing innovative medicines [2][3] Contributions and Experience - Lucera's contributions included positioning Editas financially and focusing on talent development, which helped prepare Parison for her new role [3][4] - Parison has over 18 years of experience in finance and accounting within the life sciences sector, having held various roles at Editas and previously at Rubius Therapeutics and Vertex Pharmaceuticals [4] Company Overview - Editas Medicine is a pioneering gene editing company focused on developing in vivo medicines using CRISPR technology to treat serious diseases [5]